Aligos Therapeutics Inc. (ALGS) is priced at $1.81 after the most recent trading session. At the very opening of the session, the stock price was $1.94 and reached a high price of $2.01, prior to closing the session it reached the value of $1.93. The stock touched a low price of $1.75.Recently in News on January 5, 2023, Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009. – Final cohort of Phase 1 study projected to be complete in H1 2023 –. You can read further details here
Aligos Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.4100 on 01/17/23, with the lowest value was $0.8800 for the same time period, recorded on 01/04/23.
Aligos Therapeutics Inc. (ALGS) full year performance was -40.26%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Aligos Therapeutics Inc. shares are logging -45.48% during the 52-week period from high price, and 115.45% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.84 and $3.32.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 560141 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Aligos Therapeutics Inc. (ALGS) recorded performance in the market was 89.95%, having the revenues showcasing 74.04% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 76.35M, as it employees total of 89 workers.
Aligos Therapeutics Inc. (ALGS) in the eye of market guru’s
During the last month, 0 analysts gave the Aligos Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.1345, with a change in the price was noted +0.59. In a similar fashion, Aligos Therapeutics Inc. posted a movement of +48.36% for the period of last 100 days, recording 271,394 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ALGS is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Aligos Therapeutics Inc. (ALGS): Stocks Technical analysis and Trends
Raw Stochastic average of Aligos Therapeutics Inc. in the period of last 50 days is set at 61.78%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 61.78%. In the last 20 days, the company’s Stochastic %K was 69.64% and its Stochastic %D was recorded 74.03%.
If we look into the earlier routines of Aligos Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 89.95%. Additionally, trading for the stock in the period of the last six months notably improved by 31.16%, alongside a downfall of -40.26% for the period of the last 12 months. The shares increased approximately by -10.40% in the 7-day charts and went down by 92.53% in the period of the last 30 days. Common stock shares were driven by 74.04% during last recorded quarter.